AZ's Forxiga and Taiho's Lonsurf get Japanese approval
This article was originally published in Scrip
Among the latest approvals from the Japanese Ministry of Health, Labour and Welfare (MHLW) are AstraZeneca's new diabetes treatment Forxiga (dapagliflozin), and Taiho's oral combination anticancer drug Lonsurf (trifluridine and tipiracil hydrochloride).
You may also be interested in...
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.